SCHEMBL6320440

SCHEMBL6320440

Cc1[nH]c(C=C2C(=O)Nc3cccc(-c4ccc(OC(F)(F)F)cc4)c32)c(C)c1C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALK Q9UM73 4/20 0.52
FLT3 P36888 12/20 0.51
PDGFRB P09619 5/20 0.51
RET P07949 4/20 0.51
FGFR1 P11362 4/20 0.51
ABL1 P00519 1/20 0.51
KDR P35968 9/20 0.48
FLT4 P35916 5/20 0.48
KIT P10721 2/20 0.48
AURKB Q96GD4 8/20 0.47
AURKA O14965 3/20 0.47
MET P08581 2/20 0.47
AURKC Q9UQB9 2/20 0.47
EGFR P00533 1/20 0.45
PDGFRA P16234 1/20 0.45
FLT1 P17948 2/20 0.42
MAP4K2 Q12851 2/20 0.42
STK3 Q13188 2/20 0.42
PRKAA1 Q13131 2/20 0.42
GAK O14976 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6320435 1.00 ALK (0.52) ALKFLT3PDGFRBRETFGFR1
SCHEMBL6324202 0.89 FLT3 (0.60) ALKFLT3PDGFRBRETFGFR1
SCHEMBL6324208 0.89 FLT3 (0.60) ALKFLT3PDGFRBRETFGFR1
SCHEMBL6321012 0.87 ALK (0.65) ALKFLT3PDGFRBRETFGFR1
SCHEMBL6321006 0.87 ALK (0.65) ALKFLT3PDGFRBRETFGFR1
SCHEMBL16090378 0.87 ALK (0.56) ALKFLT3PDGFRBRETFGFR1
SCHEMBL6321986 0.87 ALK (0.58) ALKFLT3PDGFRBRETFGFR1
SCHEMBL6321989 0.87 ALK (0.58) ALKFLT3PDGFRBRETFGFR1
SCHEMBL6323955 0.86 FLT3 (0.49) ALKFLT3PDGFRBRETFGFR1
SCHEMBL6323951 0.86 FLT3 (0.49) ALKFLT3PDGFRBRETFGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6677368-B2 4-aryl substituted indolinones SUGEN, INC. 2004-01-13 US claimed
EP-1349852-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES Sugen, Inc. (US) 2003-10-08 EP claimed
US-20030069297-A1 4-aryl substituted indolinones SUGEN, INC. 2003-04-10 US claimed
WO-2002055517-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES CUI JINGRONG (US) 2002-07-18 WO claimed
US-6861418-B2 4-aryl substituted indolinones SUGEN, INC. (US) 2005-03-01 US disclosed
US-20040157909-A1 4-Aryl substituted indolinones SUGEN, INC. 2004-08-12 US disclosed
US-6677368-B2 4-aryl substituted indolinones SUGEN, INC. 2004-01-13 US disclosed
EP-1349852-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES Sugen, Inc. (US) 2003-10-08 EP disclosed
US-20030069297-A1 4-aryl substituted indolinones SUGEN, INC. 2003-04-10 US disclosed
WO-2002055517-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES CUI JINGRONG (US) 2002-07-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069297-A1 4-aryl substituted indolinones CDK5, CAMK4, TNK2 ALK 1015/4885FLT3 596/4885PDGFRB 575/4885
US-20040157909-A1 4-Aryl substituted indolinones CDK5, CAMK4, TNK2 ALK 1015/4885FLT3 596/4885PDGFRB 575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.